Related references
Note: Only part of the references are listed.Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information
Linda P. Feeley et al.
MODERN PATHOLOGY (2014)
Effect of ASCO/CAP Guidelines for Determining ER Status on Molecular Subtype
Brenda Deyarmin et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Prognostic Significance of Progesterone Receptor-Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer
Aleix Prat et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Hormone receptor expression in breast cancer: postanalytical issues
Ming Lee et al.
JOURNAL OF CLINICAL PATHOLOGY (2013)
Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers
Kanwal P. S. Raghav et al.
CANCER (2012)
Low-Estrogen Receptor-Positive Breast Cancer: The Impact of Tissue Sampling, Choice of Antibody, and Molecular Subtyping
Emad A. Rakha et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry
Takayuki Iwamoto et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2011)
Dual roles of estrogen metabolism in mammary carcinogenesis
Minsun Chang
BMB REPORTS (2011)
High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer
Yumi Endo et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2011)
Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
Mitch Dowsett et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
C. Davies et al.
LANCET (2011)
ASCO-CAP Guidelines for Breast Predictive Factor Testing: An Update
M. Elizabeth Hale Hammond
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2011)
A Lower Allred Score for Progesterone Receptor Is Strongly Associated With a Higher Recurrence Score of 21-Gene Assay in Breast Cancer
Ping Tang et al.
CANCER INVESTIGATION (2010)
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Breast pathology: beyond morphology
Peter T. Simpson et al.
SEMINARS IN DIAGNOSTIC PATHOLOGY (2010)
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2009)
Molecular profiles of progesterone receptor loss in human breast tumors
Chad J. Creighton et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications
S. Badve et al.
JOURNAL OF CLINICAL PATHOLOGY (2009)
Delay to formalin fixation effect on breast biomarkers
Thaer Khoury et al.
MODERN PATHOLOGY (2009)
Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas
Bing Wei et al.
HUMAN PATHOLOGY (2008)
Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer:: Predictive value of centrally reviewed expression of estrogen and progesterone receptors -: International Breast Cancer Study Group
Giuseppe Viale et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer:: BIG 1-98
Giuseppe Viale et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Different clinical impact of estradiol receptor determination according to the analytical method: a study on 1940 breast cancer patients over a period of 16 consecutive years
N Magne et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy
XJ Cui et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Meeting highlights:: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005
A Goldhirsch et al.
ANNALS OF ONCOLOGY (2005)
Bone metastases from breast carcinoma: histopathological-radiological correlations and prognostic features
JJ James et al.
BRITISH JOURNAL OF CANCER (2003)
Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma
NS Goldstein et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2003)
Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases
VJ Bardou et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis
EF Solomayer et al.
BREAST CANCER RESEARCH AND TREATMENT (2000)
Share Paper
